Anterogen.Co.,Ltd. (065660.KQ)
KRW 16060.0
(-6.3%)
KRW 16060.0
(-6.3%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.84 Billion KRW | 58.45% |
| 2022 | -6.83 Billion KRW | -1134.17% |
| 2021 | -553.98 Million KRW | 87.34% |
| 2020 | -4.37 Billion KRW | -8.03% |
| 2019 | -4.04 Billion KRW | -321.09% |
| 2018 | -961.75 Million KRW | -315.29% |
| 2017 | 446.73 Million KRW | 20.2% |
| 2016 | 371.65 Million KRW | 737.4% |
| 2015 | -58.3 Million KRW | 95.88% |
| 2014 | -1.41 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -517.96 Million KRW | 9.36% |
| 2024 Q1 | -571.46 Million KRW | -199.75% |
| 2023 Q4 | -190.64 Million KRW | 81.56% |
| 2023 Q3 | -1.03 Billion KRW | 37.48% |
| 2023 Q2 | -1.65 Billion KRW | -4526.99% |
| 2023 FY | -2.84 Billion KRW | 58.45% |
| 2023 Q1 | 37.35 Million KRW | 106.46% |
| 2022 Q2 | -2.14 Billion KRW | 17.84% |
| 2022 Q1 | -2.6 Billion KRW | -1249.83% |
| 2022 Q4 | -578.15 Million KRW | 61.68% |
| 2022 Q3 | -1.5 Billion KRW | 29.57% |
| 2022 FY | -6.83 Billion KRW | -1134.17% |
| 2021 Q3 | -403.95 Million KRW | -114.14% |
| 2021 Q2 | 2.85 Billion KRW | 201.53% |
| 2021 Q4 | -193.18 Million KRW | 52.18% |
| 2021 FY | -553.98 Million KRW | 87.34% |
| 2021 Q1 | -2.81 Billion KRW | -187.79% |
| 2020 Q4 | -977.96 Million KRW | -199.4% |
| 2020 Q3 | 983.87 Million KRW | 128.79% |
| 2020 Q2 | -3.41 Billion KRW | -254.72% |
| 2020 Q1 | -963.43 Million KRW | 70.88% |
| 2020 FY | -4.37 Billion KRW | -8.03% |
| 2019 FY | -4.04 Billion KRW | -321.09% |
| 2019 Q4 | -3.3 Billion KRW | -594.42% |
| 2019 Q3 | -476.38 Million KRW | -184.75% |
| 2019 Q2 | 562.07 Million KRW | 167.93% |
| 2019 Q1 | -827.45 Million KRW | -145.09% |
| 2018 Q3 | -1.21 Billion KRW | 8.18% |
| 2018 Q4 | 1.83 Billion KRW | 251.57% |
| 2018 Q1 | -267.56 Million KRW | -553.54% |
| 2018 Q2 | -1.31 Billion KRW | -392.81% |
| 2018 FY | -961.75 Million KRW | -315.29% |
| 2017 Q1 | 626.87 Million KRW | 221.32% |
| 2017 Q3 | 368.22 Million KRW | 216.77% |
| 2017 Q2 | -315.33 Million KRW | -150.3% |
| 2017 Q4 | 58.99 Million KRW | -83.98% |
| 2017 FY | 446.73 Million KRW | 20.2% |
| 2016 Q3 | 101.76 Million KRW | 127.84% |
| 2016 Q4 | -516.7 Million KRW | -607.72% |
| 2016 Q2 | -365.58 Million KRW | -131.73% |
| 2016 Q1 | 1.15 Billion KRW | 6675.6% |
| 2016 FY | 371.65 Million KRW | 737.4% |
| 2015 Q2 | -376.62 Million KRW | -55.16% |
| 2015 FY | -58.3 Million KRW | 95.88% |
| 2015 Q3 | 578.58 Million KRW | 253.62% |
| 2015 Q4 | -17.52 Million KRW | -103.03% |
| 2015 Q1 | -242.74 Million KRW | 0.0% |
| 2014 FY | -1.41 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| HLB Co., Ltd. | -189.07 Billion KRW | 98.498% |
| iNtRON Biotechnology, Inc. | -9.69 Billion KRW | 70.699% |
| BINEX Co., Ltd. | 4.67 Billion KRW | 160.822% |
| Bioneer Corporation | -10.58 Billion KRW | 73.167% |
| MEDIPOST Co., Ltd. | 5.83 Billion KRW | 148.645% |
| CrystalGenomics, Inc. | -48.92 Billion KRW | 94.193% |
| Helixmith Co., Ltd | -64.08 Billion KRW | 95.567% |
| Chabiotech Co.,Ltd. | -8.43 Billion KRW | 66.306% |
| Medy-Tox Inc. | 9.75 Billion KRW | 129.122% |
| Peptron, Inc. | -15.92 Billion KRW | 82.158% |
| Amicogen, Inc. | -23.28 Billion KRW | 87.802% |
| Genexine, Inc. | -66.87 Billion KRW | 95.752% |
| HLB Therapeutics Co.,Ltd. | -2.3 Billion KRW | -23.399% |
| LegoChem Biosciences, Inc. | -73.7 Billion KRW | 96.146% |
| ALTEOGEN Inc. | -3.37 Billion KRW | 15.746% |
| PharmaResearch Co., Ltd. | 76.55 Billion KRW | 103.711% |
| SillaJen, Inc. | -20.36 Billion KRW | 86.053% |
| JETEMA, Co., Ltd. | 13.96 Billion KRW | 120.341% |
| OliX Pharmaceuticals,Inc | -19.1 Billion KRW | 85.128% |
| Genomictree Inc. | -8.75 Billion KRW | 67.556% |
| MedPacto, Inc. | -35.32 Billion KRW | 91.958% |
| D&D Pharmatech | 3.93 Billion KRW | 172.216% |
| EASY BIO,Inc. | 15.54 Billion KRW | 118.276% |
| GI Innovation, Inc. | -55.49 Billion KRW | 94.881% |